Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Lenzilumab |
| Synonyms | |
| Therapy Description |
Lenzilumab (KB003) is an antibody that targets granulocyte macrophage colony-stimulating factor (GM-CSF), potentially resulting in increased apoptosis and decreased proliferation of tumor cells (PMID: 32294158). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Lenzilumab | KB003|KB 003 | Lenzilumab (KB003) is an antibody that targets granulocyte macrophage colony-stimulating factor (GM-CSF), potentially resulting in increased apoptosis and decreased proliferation of tumor cells (PMID: 32294158). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|